No Data
No Data
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges
RBC Capital Remains a Hold on Design Therapeutics (DSGN)
Design Therapeutics Reports Q3 EPS (23c), Consensus (24c)
Design Therapeutics | 10-Q: Q3 2024 Earnings Report
Design Therapeutics | 8-K: Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC TM Portfolio